Showing results (161-170 of 261) with videos related to

Sort By:
Pageof 27
Acta Dermato-Venereologica|February 3, 2016
Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque PsoriasisJeffrey M Sobell, Peter Foley, Darryl Toth, et al.
The Journal of Dermatological Treatment|May 11, 2016
Adherence to topical therapies in actinic keratosis: A literature reviewPeter Foley, Eggert Stockfleth, Ketty Peris, et al.
The Australasian Journal of Dermatology|July 13, 2016
The Australasian Psoriasis Collaboration view on methotrexate for psoriasis in the Australasian settingMarius Rademaker, Monisha Gupta, Megan Andrews, et al.
ACS Biomaterials Science & Engineering|October 4, 2023
Layer-by-Layer Analysis of <i>In Vitro</i> Skin ModelsElizabeth Footner, Kate Firipis, Emily Liu, et al.
Orthopaedic Journal of Sports Medicine|July 9, 2026
Intraoperative Failure of Meniscus Fixation Devices After Range of Motion Cycling: A Survey of the Pediatric Research in Sports Medicine Society MembershipNicholas Bast, Hayley Ditmars, Christopher Baker, et al.
The Australasian Journal of Dermatology|September 20, 2022
Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian settingPeter Foley, Yves A Kerdraon, John P Hogden, et al.
International Journal of Dermatology|April 14, 2015
A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosisEggert Stockfleth, Ketty Peris, Carlos Guillen, et al.
American Journal of Clinical Dermatology|September 10, 2020
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 StudyKristian Reich, April W Armstrong, Peter Foley, et al.
JAMA Dermatology|May 26, 2018
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical TrialsPeter Foley, Kenneth Gordon, Christopher E M Griffiths, et al.
Journal of the American Academy of Dermatology|January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trialKristian Reich, April W Armstrong, Peter Foley, et al.
Pageof 27